


Company Announcement No. 16/2011 - 3 November 2011

# Announcement of full-year financial results 2010/11

1 September 2010 - 31 August 2011




**CHR HANSEN**
*Improving food & health*

*"During the year the global economy has been through turbulent times with significant uncertainty. With such global turmoil we are pleased that Chr. Hansen once again can report a strong performance. We delivered on our financial targets for the year with profitable growth across all business areas resulting in organic growth of 14%. Excluding the effect of carmine prices, organic growth reached 10%. The positive development is a clear evidence of the resilience and scalability of our business model.*

*We continue on track to meet our long term growth expectations and expect organic growth in 2011/12 to reach 7-10% excluding the effect of carmine prices. We expect carmine prices to decline in the coming year affecting the organic growth negatively by approximately 2 percentage points to 5-8%.*

*The scalability of our business model will further improve our profitability and we expect EBIT to be above 26%." says CEO Lars Frederiksen.*

## Highlights:

- Revenue EUR 636 million, up 15% compared to 2009/10. Organic growth 14% (10% adjusted for increased sales prices to reflect higher raw material prices for carmine)
- EBIT before special items (b.s.i.) EUR 159 million, up 14% compared to 2009/10. EBIT margin before special items 25%, unchanged from 2009/10
- Tax EUR 34 million corresponding to an effective tax rate of 23% compared to 63% last year
- Net profit for the year EUR 119 million compared to EUR 19 million in 2009/10
- Free cash flow EUR 125 million, doubled compared to 2009/10. EUR 19 million is related to net proceeds from the sale of the Functional Blends activities
- Net interest bearing debt EUR 348 million corresponding to 1.7 times EBITDA before special items compared to 2.6 times EBITDA before special items at August 31, 2010
- For the financial year 2010/11, a dividend of EUR 0.48 (DKK 3.57) per share corresponding to EUR 65 million is proposed. The dividend equals net cash proceeds from the sale of the Functional Blends activities plus 40% of net profit
- In Q4 2010/11 revenue EUR 162 million, up 5% compared to Q4 2009/10. Organic growth 9%. (8% adjusted for increased sales prices to reflect higher raw material prices for carmine). Operating profit (EBIT) margin b.s.i. reached 28% compared to 29% last year. Free cash flow amounted to EUR 89 million, of which EUR 19 million related to net proceeds from the sale of the Functional Blends activities, compared to EUR 31 million in Q4 2009/10
- Excluding effect on sales prices from changes to raw material prices for carmine the organic growth is expected to be in the range of 7-10%. Including the effect from change in carmine prices organic growth is expected in the range of 5-8%. EBIT margin b.s.i. is expected to be above 26%.

## Financial highlights and key ratios

This Annual Account Release is prepared in accordance with the recognition and measurement requirements of IFRS<sup>®</sup> as adopted by the EU, and additional Danish regulations for the presentation of interim reports by listed companies. Furthermore, the release has been prepared in accordance with the accounting policies set out in the Annual Report 2010/11 of Chr. Hansen Holding A/S.

EUR million	Q4 2010/11	Q4 2009/10	Growth %	2010/11	2009/10	Growth %
<b>Income statement</b>						
Revenue	161.5	154.1	5%	635.6	551.8	15%
Gross profit	80.0	79.0	1%	308.7	279.3	11%
EBITDA	57.1	53.7	6%	201.7	157.7	28%
EBIT before special items	45.9	44.1	4%	159.2	139.8	14%
EBIT	45.9	42.5	8%	159.2	115.6	38%
Net profit from discontinued operations	3.3	0.8	313%	4.4	2.4	83%
Net profit	40.0	27.4	-	118.6	19.2	-
<b>Cash Flow</b>						
Cash flow from operating activities	87.1	44.2	97%	150.4	98.5	53%
Cash flow from investing activities	1.6	(13.0)	-112%	(25.8)	(38.4)	-33%
Free cash flow	88.7	31.2	184%	124.6	60.1	107%
<b>Financial position</b>						
Total assets	1,353	1,316	3%	1,353	1,316	3%
Equity, excl. minorities	641	542	18%	641	542	18%
Net working capital	98	90	8%	98	90	8%
Net interest-bearing debt	348	475	-27%	348	475	-27%
<b>Earnings per share</b>						
EPS, continuing operations, diluted	0.27	0.26		0.83	0.14	
<b>Key figures</b>						
Organic growth %	9%	12%		14%	13%	
Organic growth excl. carmine price effect %	8%	7%		10%	11%	
Gross margin %	50%	51%		49%	51%	
EBITDA margin %	35%	35%		32%	29%	
EBIT margin, before special items %	28%	29%		25%	25%	
EBIT margin %	28%	28%		25%	21%	
ROIC % - excluding goodwill	35%	33%		30%	27%	
R&D %	7%	5%		6%	6%	
Capital expenditure %	11%	8%		7%	7%	
NWC %	15%	16%		15%	16%	
Debt to EBITDA				1.7	2.6	


For 2009/10 income statement, cash flow and key ratios are restated regarding discontinued operations in Functional Blends activities in 2010/11. For 2009/10 balance sheet figures in key figures are restated, excluding discontinued operations, because of the restatement of the income statement and cash flow to make key ratios comparable.

## Management's review

### Revenue 2010/11



### Revenue growth per division (2010/11)




Revenue amounted to EUR 636 million, an increase of 15% compared to last year, corresponding to an organic growth of 14% (10% adjusted for increased sales prices to reflect higher raw material prices for carmine).

In Q4 2010/11, revenue increased by 5% corresponding to an organic revenue growth of 9% (8% adjusted for increased sales prices to reflect higher raw material prices for carmine). The organic growth was positively affected by approximately 2 percentage points from euro price list effect.

### Revenue by division

The business mix between the divisions changed during 2010/11. The Cultures & Enzymes Division accounted for 60% compared to 65% last year while the Natural Colors Division accounted for 26% of revenue compared to 21% in 2009/10.

### Revenue growth per division (Q4 2010/11)



The Health & Nutrition Division's share of revenue was unchanged at 14% compared to last year.

### Cultures & Enzymes Division


Revenue increased by 6% to EUR 379 million corresponding to organic growth of 6% in 2010/11.

In Q4 2010/11 the division experienced organic growth of 5% driven by strong growth in cultures for fermented milk while cultures for cheese and probiotic cultures only experienced modest organic growth

### Health & Nutrition Division

Revenue increased by 15% to EUR 91 million corresponding to organic growth of 16% in 2010/11.

### Revenue growth per region (2010/11)



In Q4 2010/11 organic growth in the division was 24% driven by strong sales of cultures for human health products.

#### *Natural Colors Division*

Revenue in the Natural Colors Division increased by 42% to EUR 166 million corresponding to organic growth of 40% in 2010/11 (19% adjusted for increased sales prices to reflect higher raw material prices for carmine).

In Q4 2010/11 the division experienced organic growth of 12% (6% adjusted for increased sales prices to reflect higher raw material prices for carmine).

#### **Revenue by region**


##### *European region*

(51% of total revenue in 2010/11)

Revenue increased by 14% with organic growth of 14% (10% adjusted for increased sales prices to reflect higher raw material prices for carmine).

Growth in sales of cultures was negatively affected by the current uncertainty around the European Food Safety Authority's (EFSA) assessment of documentation for health claims which affected sales of probiotic cultures negatively, while cultures for cheese and yogurt delivered good growth.

### Revenue growth per region (Q4 2010/11)



Natural colors performed strongly as conversion to natural colors continued during the year. Health & Nutrition Division also delivered strong growth driven by human health products and animal probiotics for swine.

In Q4 2010/11 the region experienced organic growth of 4%. Growth in the Cultures & Enzymes Division and in the Natural Colors Division was modest while the Health & Nutrition Division delivered strong growth.

#### *North American region*

(21% of total revenue in 2010/11)

Revenue increased by 10%, with organic growth of 10% (7% adjusted for increased sales prices to reflect higher raw material prices for carmine).

The Cultures & Enzymes Division delivered modest growth as growth in cultures for cheese was offset by negative development in probiotic cultures. The Natural Colors Division delivered strong growth albeit at a lower level than in the European and South American regions. Organic growth in the Health & Nutrition Division was strong driven by human health products.

In Q4 2010/11 the North American region experienced organic growth of 14% driven by human and animal health as well as natural colors.

*South American region  
(12% of total revenue in 2010/11)*

Revenue increased by 22%, corresponding to 19% organic growth (7% adjusted for increased sales prices to reflect higher raw material prices for carmine), driven by the conversion to natural colors. The Cultures & Enzymes Division also delivered good growth driven by cultures for fermented milk and cheese as well as enzymes.

In Q4 2010/11 organic growth in the South American region was 19% driven by natural colors, cultures and enzymes.

*APMEA region  
(16% of total revenue in 2010/11)*

Revenue increased by 23%, corresponding to 19% organic growth (16% adjusted for increased sales prices to reflect higher raw material prices for carmine).

The organic growth for cultures was strong across the region, while sales of enzymes contracted. Natural colors delivered good growth primarily driven by the ongoing conversion from synthetic colors. Despite the tragic events in Japan during the year our local organization delivered good growth driven by natural colors and cultures. Sale to the Middle East and Africa also contributed positively to the regional growth despite the political turmoil in a number of countries.

In Q4 2010/11 the APMEA region experienced organic growth of 16% driven by strong growth in cultures.

**Gross profit**

Gross profit increased to EUR 309 million, up 11% compared to last year. Gross margin decreased 2 percentage points to 49% due to the changed business mix driven by the strong growth in the Natural Colors Division. Higher raw material prices for carmine alone affected the gross margin for the Group negatively by approximately 2 percentage points.

In Q4 2010/11 gross profit amounted to EUR 80 million, an increase of 1% compared to the same period last year. Gross profit margin decreased by 1 percentage point to 50% driven by the effect from higher raw material prices for carmine.

**Expenses**

Expenses totaled EUR 150 million compared to EUR 140 million last year, an increase of 7%.

Research and Development costs amounted to EUR 28 million corresponding to an increase of 13%. Capitalized development costs amounted to EUR 16 million, an increase of EUR 5 million compared to last year.

The total Research and Development expenses excluding depreciations and amortizations of EUR 4 million amounted to EUR 40 million, corresponding to 6% of total revenue, which is at the same level as last year. The primary focus of the development activities is to support the Cultures & Enzymes Division and the Health & Nutrition Division, where Research and Development expenses correspond to 6% and 13% of revenue, respectively.

Sales and marketing expenses increased by 11% to EUR 79 million and accounted for 12% of revenue compared to 13% last year.

Administrative expenses increased by 5% to EUR 46 million and accounted for 7% of revenue compared to 8% last year.

In Q4 2010/11 expenses amounted to EUR 34 million, a decrease of 2% compared to the same period last year. Capitalized development costs amounted to EUR 6 million compared to EUR 5 million in Q4 2009/10.

**Special items**

Special items were nil in 2010/11 compared to an expense of EUR 24 million last year of which EUR 18 million related to an extraordinary bonus to all employees, reimbursed net of tax by the former majority shareholder Financière Star 1 through a capital contribution.

In Q4 2010/11 special items were nil compared to an expense of EUR 2 million last year.

**Operating profit (EBIT)**

EBIT amounted to EUR 159 million compared to EUR 116 million last year. The EBIT margin reached 25%, compared to 21% last year, with last year being negatively affected by special items. EBIT margin for the Group before special items remained unchanged at 25% despite the dilutive effect from the changed business mix.

In Q4 2010/11 EBIT for the Group amounted to EUR 46 million compared to 43 million in the same period last year. EBIT margin was 28% for Q4 2010/11 unchanged compared to the same period last year. EBIT margin before special items was 28% compared to 29% in the same period last year.

**Net financials and tax**

Net financial expenses amounted to EUR 11 million compared to EUR 67 million last year. Net interest expenses declined to EUR 14 million from EUR 60 million mainly due to full year effect of the reduced debt level from the refinancing in connection with the listing of the company in 2009/10.

In Q4 2010/11 net financial expenses amounted to EUR 2 million compared to EUR 5 million in the same period last year.

Corporation tax amounted to EUR 34 million compared to EUR 32 million last year, corresponding to an effective tax rate of 23% compared to 63% last year. The effective tax rate for 2010/2011 was positively affected

with 2 percentage points by a carry forward of interest, which was not deductible in previous years due to interest ceiling rules in Denmark.

In Q4 2010/11 corporation tax amounted to EUR 7 million compared to EUR 11 million in the same period last year. The tax rate for Q4 2010/11 was positively affected by the carry forward of interest, not deductible in previous years due to interest ceiling rules in Denmark.

**Profit/loss for the period**

Net profit amounted to EUR 119 million, compared to EUR 19 million last year, primarily due to lower net financial expenses and improved operating profit.

In Q4 2010/11 the net profit amounted to 40 million compared to EUR 27 million in the same period last year primarily due to improved operating profit, lower net financial expenses and lower tax.

**Assets**

At 31 August 2011, total assets amounted to EUR 1,353 million, which was EUR 36 million higher than last year. Total non-current assets decreased by EUR 21 million to EUR 1,056 million. Total current assets increased by EUR 57 million to EUR 297 million.

Inventories increased by EUR 3 million while receivables decreased by EUR 3 million. Cash and cash equivalents increased by EUR 57 to EUR 118 million due to the strong free cash flow.

Net working capital at 31 August 2011 was EUR 98 million equal to 15% of revenue compared to EUR 90 million, adjusted for the sale of Functional Blends activities, or 16% of revenue at 31 August 2010.

## Equity

Total equity excluding minorities at 31 August 2011 amounted to EUR 641 million, compared to EUR 542 million at the end of last year. The increase was primarily driven by profit for the year.

Dividend payments related to the financial year 2009/10 amounted to EUR 12 million.

## Net debt

Net interest bearing debt amounted to EUR 348 million at 31 August 2011, which represents 1.7 times EBITDA before special items compared to 2.6 times EBITDA before special items at 31 August 2010.

During 2010/11 total repayments of EUR 56 million were made on long term loans. EUR 46 million were voluntary repayments on a revolving loan facility.

At year end approximately 59% of the debt was secured at fixed interest rates. The total debt has an average maturity of 4.2 years compared to 4.7 years at the end of last year.

## Cash flow

Cash flow from operating activities was EUR 150 million compared to EUR 99 million last year. The increase was due to higher operating profit and lower interest payments partly offset by higher working capital and taxes paid.

Cash flow from investing activities in 2010/11 was EUR 26 million compared to EUR 38 million in 2009/10. Net cash proceeds from divested operations, related to the sale of the Functional Blends business, was positive with EUR 19 million while capitalized development cost amounted to EUR 16 million in 2010/11.

Capital expenditure in 2010/11 amounted to EUR 45 million, corresponding to 7% of revenue.

Free cash flow was EUR 125 million, compared to EUR 60 million last year.

In Q4 2010/11 cash flow from operating activities was EUR 87 million compared to EUR 44 million in the same period last year. The increase was due to improvement in working capital, lower interest payments and higher operating profit.

Cash flow from investing activities for Q4 2010/11 was positive with EUR 2 million compared to negative EUR 13 million in Q4 last year. Sale of the Functional Blends activities affected the cash flow positively with EUR 19 million.

Free cash flow was EUR 89 million in Q4 2010/11, compared to EUR 31 million last year.



## Segment information

### Cultures & Enzymes Division



EUR million	Q4 2010/11	Q4 2009/10	2010/11	2009/10
Revenue	98	97	379	356
Organic growth	5%	2%	6%	6%
EBITDA	42	42	143	138
EBITDA margin	43%	43%	38%	39%
EBIT	34	33	111	104
EBIT margin	34%	34%	29%	29%

Revenue increased by 6% to EUR 379 million in 2010/11. The organic growth of 6% for the division was primarily driven by increased sales of cultures for fermented milk and cheese products which combined accounted for around 50% of total revenue in the division. Continued conversion from bulk starter to Direct Vat Set® cultures contributed to the growth.

The organic growth was negatively impacted by reduction in sales of probiotic cultures primarily related to the current uncertainty around EFSA assessment of documentation for health claims. Probiotic cultures accounted for approximately 20% of revenue.

Enzymes, which accounted for approximately 20% of revenue, delivered low organic growth in line with previous years.

Wine and Meat accounted for approximately 10% of revenue. Wine delivered strong growth as a new product (Viniflora®

FrootZen™ Pichia kluyveri) was launched while meat delivered stable growth.

In Q4 2010/11 organic growth was 5%. The organic growth was positively affected by approximately 2 percentage point from depreciation of currencies in countries where we today price based on euro pricelist.

In 2010/11 EBIT was EUR 111 million or 7% above last year.

EBIT margin for 2010/11 was 29% and remained at the same level as last year despite scalability gains. Strong growth in Asia and South America combined with higher oil prices led to increased distribution costs as production facilities are located in Europe and USA. Changed product mix also affected the margin for the division negatively.

EBIT margin for Q4 remained at the same level as in Q4 2009/10.

## Health & Nutrition Division



EUR million	Q4 2010/11	Q4 2009/10	2010/11	2009/10
Revenue	24	20	91	79
Organic growth	24%	2%	16%	14%
EBITDA	11	9	37	28
EBITDA margin	46%	42%	40%	35%
EBIT	9	7	30	23
EBIT margin	39%	35%	33%	29%

In 2010/11 the Health & Nutrition Division achieved organic growth of 16% resulting in revenue of EUR 91 million. The human health area experienced growth in all application areas driven by new customer projects, while growth in animal health primarily originated from earlier product launches.

In Q4 2010/11 organic growth was 24% primarily driven by strong sale of cultures for human health products. Quarterly growth in the Health & Nutrition Division remains significantly affected by timing of orders.

For 2010/11 EBIT was EUR 30 million compared to EUR 23 million last year corresponding to an increase of 31%. The EBIT margin improved 4 percentage points to 33%. The improvement was driven by scalability effects from the increased sales volume.

In Q4 2010/11 EBIT margin was 39% compared to 35% in Q4 last year. The improvement was driven by scalability effects from the increased sales volume.

## Natural Colors Division



EUR million	Q4 2010/11	Q4 2009/10	2010/11	2009/10
Revenue	40	37	166	117
Organic growth	12%	66%	40%	42%
EBITDA	4	5	22	16
EBITDA margin	11%	14%	13%	14%
EBIT	3	4	18	12
EBIT margin	8%	10%	11%	11%

Revenue in the Natural Colors Division increased by 42% to EUR 166 million with organic growth of 40% in 2010/11 (19% adjusted for increased sales prices to reflect higher raw material prices for carmine). The growth was driven by the continued conversion trend of replacing synthetic colors with natural colors, combined with our presence among market leading customers.

The conversion to natural colors continued across all regions although strongest in Europe and South America. During the year sales prices were adjusted to reflect the increase in raw material prices for carmine.

In Q4 2010/11 organic growth was 12%, (6% adjusted for increased sales prices to reflect higher raw material prices for carmine). Raw material prices for carmine remained volatile but decreased to around USD 60/kilogram by the end of the financial year.

In 2010/11 EBIT for the Natural Colors Division was EUR 18 million, an increase of EUR 5 million or 42% compared to last year.

EBIT margin for 2010/11 was 11% unchanged compared to last year. Scalability effects

from increased sales volume were offset by a negative effect from higher raw materials prices for carmine.

To capture the growth opportunities within natural colors Research and Development facilities in France and production facilities in Peru and Copenhagen were upgraded during 2010/11.

In Q4 2010/11 EBIT margin decreased to 8% from 10% in the same period last year. This was driven by inventory write-downs related to the drop in carmine prices experienced in the last part of Q4 2010/11. Excluding write-downs the EBIT margin would have been above last year.

To optimize the business portfolio and to focus on areas where Chr. Hansen holds leading positions it was decided to sell the majority of the Group's Functional Blends activities to Frutarom Industries Ltd. at a total consideration of EUR 23 million. The transaction was closed on 31 July 2011. As a consequence of the exit the "Colors & Blends Division" changed name to "Natural Colors Division".

## Outlook

### Outlook 2011/12

The financial year 2011/12 has started positively for Chr. Hansen. Revenue growth continues to be driven by increased demand for healthy food products not least from the growing middle income population in emerging markets and conversion from in-house bulk starter to industrialized produced cultures and from synthetic to natural colors. Probiotic cultures used in fermented milk products remain affected by the current uncertainty around health claims.

Raw material prices for the natural color carmine have decreased in the beginning of the financial year and prices for 2011/12 are expected to be significantly below 2010/11. However, volatility remains significant and the expected price level is subject to considerable uncertainty.

Excluding effect on sales prices from changes to raw material prices for carmine the organic growth is expected to be in the range of 7-10% driven by growth in all three divisions. Including the effect from change in carmine prices organic growth is expected in the range of 5-8%

EBIT margin b.s.i. is expected to be above 26% driven by Chr. Hansen's scalable business model and the impact from decreasing raw material prices for carmine.

The required level of clinical documentation to support health claims on functional food and food supplements have increased especially in Europe. Expenses related to clinical studies are expected to increase in 2011/12 as we build additional clinical documentation on our core probiotic cultures.

Research and Development expenditure (costs and capitalization) excluding amortization is expected to be around 7% in 2011/12.

As a consequence of the expected increase in spend on clinical studies and expected

increase in investments in the Natural Colors Division to capture the growth potential from continued conversion, capital expenditure as a percentage of revenue is expected to be above last year. Free cash flow before acquisitions and divestments is expected to be above last year.

### Long term financial ambition (2-4 years)

Annual revenue is expected to grow organically in the range of 8-10%. EBIT margin b.s.i. is expected to increase gradually, assuming an unchanged business mix. Net working capital is expected to be 14-17% of revenue. Capital expenditure is expected to be in the range of 7.5-8.5% of revenue. The increase in capital expenditure (compared to previous guidance of 6.5-7.5% of revenue) is driven by the expected increase in spend on clinical studies and increase in investments in Natural Colors over the coming 2-4 years.

Research & Development expenditure (costs and capitalization) excluding amortization is expected to be between 6-7% of revenue.

Consequently a high cash conversion is expected and net debt leverage is expected to be between 2-2.5 times EBITDA with excess capital distributed to shareholders.

The 2011/12 outlook and long term financial ambition are sensitive to major changes in the global economy including the USD exchange rate and raw material prices for carmine which could impact the expected result for Chr. Hansen.

### Change in dividend policy

The Board of Directors have decided to change Chr. Hansen Holding A/S' dividend policy from 2011/12. The pay-out ratio is changed from between 30%-40% to 30%-50% of net profit. Proposal of dividends depends on the Board's assessment of factors such as business development, growth strategy and financing needs and there can be no assurance that in any given year a dividend will be proposed or declared.

## Statement of the Board of Directors and Executive Board

The Board of Directors and Executive Board today considered and approved the audited Consolidated Financial Statements in the Annual Report of Chr. Hansen Holding A/S for the financial year ended 31 August 2011.

The Board of Directors and Executive Board also approved this unaudited Annual Account Release containing financial information for Q4 2010/11 and condensed financial information for the financial year ended 31 August 2011.

The Consolidated Financial Statements in the Annual Report have been prepared in accordance with the International Financial Reporting Standards as adopted by the EU. In addition, the Annual Report has been presented in accordance with additional Danish disclosure requirements for listed companies. We consider the accounting policies used to be appropriate and the accounting estimates reasonable, and in our opinion, the Consolidated Financial Statements in the Annual Report give a true and fair view of the Group's assets, liabilities and financial position at 31 August 2011 and of the results of the Group's operations and cash flows.

This Annual Account Release has been prepared in accordance with the accounting policies as applied in the Consolidated Financial Statements for the financial year ended 31 August 2011 and additional Danish disclosure requirements for listed companies, and in our opinion the overall presentation of this Annual Account Release is adequate.

We further consider that the Management's Review in the preceding pages includes a true and fair account of the development and performance of the Group, the results for the year and of the financial position, together with a description of the principal risks and uncertainties that the Group faces in accordance with Danish disclosure requirements for listed companies.

Hoersholm, 3 November 2011

### Executive Board:

Lars Frederiksen  
President and CEO

Klaus Pedersen  
Chief Financial Officer

Knud Vindfeldt  
Executive Vice President

Henrik Dalboege  
Executive Vice President

Carsten Hellmann  
Executive Vice President

Jesper Allentoft  
Executive Vice President

Carsten Bennike  
Executive Vice President

### Board of Directors:

Ole Andersen  
Chairman

Frédéric Stévenin  
Vice Chairman

Henrik Poulsen

Alice Dautry

Gaëlle d'Engremont

Mark A. Wilson

Joergen O. Nielsen

Svend Laulund

Martin G. Seidel

## Additional information

### Conference call

Chr. Hansen will host a conference call on 3 November 2011 at 9:30 am CET. The conference call can be accessed at our home page [www.chr-hansen.com](http://www.chr-hansen.com).

### For further information, please contact:

Lars Frederiksen, CEO  
Tel: +45 45 74 74 74

Klaus Pedersen, CFO  
Tel: +45 45 74 74 74

Anders Mohr Christensen, Investor Relations  
Tel: +45 45 74 76 18

### Financial Calendar 2010/11

29 November 2011 Annual General Meeting

### Financial Calendar 2011/12

11 January	2012	Interim Report (Q1 2011/2012)
19 April	2012	Interim Report (Q2 2011/2012)
4 July	2012	Interim Report (Q3 2011/2012)
31 October	2012	Annual Report 2011/2012
27 November	2012	Annual General Meeting

### Forward-looking statements

This report contains forward-looking statements. Such statements are subject to risks and uncertainties as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in this report.

### Governing text

The report has been translated from Danish. The Danish text shall govern for all purposes and prevail in the event of any discrepancy between the versions.

### About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products are centered around cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2010/11 financial year was EUR 636 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,300 dedicated employees in over 30 countries. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen. For further information, please visit [www.chr-hansen.com](http://www.chr-hansen.com).

Chr. Hansen Holding A/S  
Boege Allé 10-12  
DK-2970 Hoersholm  
Denmark

Tel. +45 45 74 74 74  
[www.chr-hansen.com](http://www.chr-hansen.com)  
Company reg: 28318677

## INCOME STATEMENT SEPTEMBER 1 - AUGUST 31

EUR million	Q4 2010/11	Q4 2009/10	2010/11	2009/10
<b>Revenue</b>	161.5	154.1	635.6	551.8
Cost of sales	(81.5)	(75.1)	(326.9)	(272.5)
<b>Gross profit</b>	<b>80.0</b>	<b>79.0</b>	<b>308.7</b>	<b>279.3</b>
Expenses	(34.1)	(34.9)	(149.5)	(139.5)
<b>Operating profit before special items</b>	<b>45.9</b>	<b>44.1</b>	<b>159.2</b>	<b>139.8</b>
Special items	-	(1.6)	-	(24.2)
<b>Operating profit</b>	<b>45.9</b>	<b>42.5</b>	<b>159.2</b>	<b>115.6</b>
Net financial expenses	(1.9)	(4.8)	(10.9)	(67.0)
<b>Profit/Loss before tax</b>	<b>44.0</b>	<b>37.7</b>	<b>148.3</b>	<b>48.6</b>
Corporation tax	(7.3)	(11.1)	(34.1)	(31.8)
<b>Profit/Loss from continued operations</b>	<b>36.7</b>	<b>26.6</b>	<b>114.2</b>	<b>16.8</b>
Profit from discontinued operations	3.3	0.8	4.4	2.4
<b>Profit/Loss for the period</b>	<b>40.0</b>	<b>27.4</b>	<b>118.6</b>	<b>19.2</b>
Distributed to:				
Minority interests	0.6	0.4	1.9	1.4
<b>Shareholders of Chr. Hansen Holding A/S</b>	<b>39.4</b>	<b>27.0</b>	<b>116.7</b>	<b>17.8</b>
<b>Earnings per share, EUR:</b>				
Earnings per share, continuing operations	0.27	0.26	0.83	0.14
Earnings per share, continuing operations diluted	0.27	0.26	0.83	0.14
Earnings per share, discontinued operations	0.02	0.01	0.03	0.02
Earnings per share, discontinued operations diluted	0.02	0.01	0.03	0.02

## STATEMENT OF COMPREHENSIVE INCOME SEPTEMBER 1 - AUGUST 31

EUR million	Q4 2010/11	Q4 2009/10	2010/11	2009/10
<b>Profit/Loss for the period</b>	<b>40.0</b>	<b>27.4</b>	<b>118.6</b>	<b>19.2</b>
Currency translation of foreign group enterprises	(2.8)	(4.4)	(10.1)	21.4
Cash flow hedge	(8.7)	(1.5)	(0.6)	(1.5)
Tax related to cash flow hedge	2.0	0.3	0.2	0.3
<b>Other comprehensive income for the period</b>	<b>(9.5)</b>	<b>(5.6)</b>	<b>(10.5)</b>	<b>20.2</b>
<b>Total comprehensive income for the period</b>	<b>30.5</b>	<b>21.8</b>	<b>108.1</b>	<b>39.4</b>
Distributed to:				
Shareholders of Chr. Hansen Holding A/S	30.3	21.5	107.4	37.8
Minority interests	0.2	0.3	0.7	1.6
	<b>30.5</b>	<b>21.8</b>	<b>108.1</b>	<b>39.4</b>



## STATEMENT OF FINANCIAL POSITION

## Assets

EUR million	Aug 31, 2011	Aug 31, 2010
<b>Non-current assets</b>		
<b>Intangible assets</b>		
Goodwill	611.3	625.6
Other intangible assets	150.1	155.1
Intangible assets in progress	42.5	35.1
	<b>803.9</b>	<b>815.8</b>
<b>Property, plant and equipment</b>		
Land and buildings	122.1	136.3
Plant and machinery	95.5	100.3
Other fixtures and equipment	8.9	6.9
Property, plant and equipment in progress	17.6	15.0
	<b>244.1</b>	<b>258.5</b>
<b>Other non-current assets</b>		
Deferred tax	7.7	2.2
	<b>7.7</b>	<b>2.2</b>
<b>Total non-current assets</b>	<b>1,055.7</b>	<b>1,076.5</b>
<b>Current assets</b>		
<b>Inventories</b>		
Raw materials and consumables	16.7	12.1
Work in progress	23.9	20.5
Finished goods and goods for resale	37.5	42.7
	<b>78.1</b>	<b>75.3</b>
<b>Receivables</b>		
Trade receivables	85.6	82.9
Tax receivables	2.3	6.7
Other receivables	7.6	8.2
Prepayments	5.3	5.7
	<b>100.8</b>	<b>103.5</b>
<b>Cash and cash equivalents</b>	<b>118.1</b>	<b>61.0</b>
<b>Total current assets</b>	<b>297.0</b>	<b>239.8</b>
<b>Total assets</b>	<b>1,352.7</b>	<b>1,316.3</b>

## STATEMENT OF FINANCIAL POSITION

## Equity and liabilities

EUR million	Aug 31, 2011	Aug 31, 2010
<b>Equity</b>		
Share capital	185.3	185.4
Reserves	455.3	356.6
Minority interests	3.7	3.7
<b>Total equity</b>	<b>644.3</b>	<b>545.7</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Employee benefit obligations	5.2	5.4
Deferred tax	69.2	71.3
Provisions	1.2	2.8
Borrowings	434.9	523.9
Corporation tax	16.0	8.9
Other non-current debt	2.3	2.3
	<b>528.8</b>	<b>614.6</b>
<b>Current liabilities</b>		
Provisions	1.0	0.8
Borrowings	30.7	11.6
Payable to Parent Company	-	-
Prepayments from customers	0.4	0.2
Trade payables	66.2	64.6
Corporation tax	34.8	26.3
Other payables	46.5	52.5
Liabilities regarding disposal group held for sale	-	-
	<b>179.6</b>	<b>156.0</b>
<b>Total liabilities</b>	<b>708.4</b>	<b>770.6</b>
<b>Total equity and liabilities</b>	<b>1,352.7</b>	<b>1,316.3</b>

## STATEMENT OF CHANGES IN EQUITY

September 1, 2010 - Aug 31, 2011

EUR million	Shareholders of Chr. Hansen Holding A/S							Total
	Share capital	Treasury shares	Currency trans-lation	Cash flow hedge	Retained earnings	Total	Minority interests	
<b>Balance</b>								
<b>September 1, 2010</b>	185.4	(35.0)	2.7	(1.2)	390.1	542.0	3.7	545.7
Total comprehensive income for the period, cf. Statement of comprehensive income	(0.1)		(8.8)	(0.4)	116.7	107.4	0.7	108.1
Share-based payment					2.8	2.8	-	2.8
Dividend					(11.6)	(11.6)	(0.7)	(12.3)
<b>Balance</b>								
<b>August 31, 2011</b>	185.3	(35.0)	(6.1)	(1.6)	498.0	640.6	3.7	644.3

Sep 1, 2009 - Aug 31, 2010

EUR million	Shareholders of Chr. Hansen Holding A/S							Total
	Share capital	Treasury shares	Currency trans-lation	Cash flow hedge	Retained earnings	Total	Minority interests	
<b>Balance</b>								
<b>September 1, 2009</b>	135.5	-	(18.6)	-	(25.9)	91.0	2.8	93.8
Capital increase	50.0	-	-	-	400.0	450.0	-	450.0
IPO-related cost	-	-	-	-	(18.6)	(18.6)	-	(18.6)
Capital contribution	-	-	-	-	15.6	15.6	-	15.6
Purchase of treasury shares	-	(35.0)	-	-	-	(35.0)	-	(35.0)
income for the period, cf. Statement of comprehensive income	(0.1)	-	21.3	(1.2)	17.8	37.8	1.6	39.4
Share-based payment	-	-	-	-	1.2	1.2	-	1.2
Dividend	-	-	-	-	-	-	(0.7)	(0.7)
<b>Balance</b>								
<b>August 31, 2010</b>	185.4	(35.0)	2.7	(1.2)	390.1	542.0	3.7	545.7

## STATEMENT OF CASH FLOWS SEPTEMBER 1 - AUGUST 31

EUR million	Q4 2010/11	Q4 2009/10	2010/11	2009/10
<b>Operating profit</b>	<b>45.9</b>	<b>42.5</b>	<b>159.2</b>	<b>115.6</b>
Adjustments	14.7	12.8	45.9	43.8
Change in working capital	32.7	0.9	(19.4)	(9.6)
Interest payments received	1.3	5.6	1.3	5.9
Interest payments made	(4.7)	(14.0)	(15.2)	(45.7)
Taxes paid	(2.8)	(3.6)	(21.4)	(11.5)
<b>Cash flow from operating activities</b>	<b>87.1</b>	<b>44.2</b>	<b>150.4</b>	<b>98.5</b>
Proceeds from divested operations	19.4	-	19.4	-
Investments in intangible assets	(7.9)	(8.5)	(23.3)	(20.0)
Investments in property, plant and equipment	(10.1)	(4.8)	(22.1)	(18.7)
Sale of property, plant and equipment	0.2	0.3	0.2	0.3
<b>Cash flow from investing activities</b>	<b>1.6</b>	<b>(13.0)</b>	<b>(25.8)</b>	<b>(38.4)</b>
<b>Free cash flow</b>	<b>88.7</b>	<b>31.2</b>	<b>124.6</b>	<b>60.1</b>
Capital contribution	-	447.0	-	447.0
Raising of long-term loans	-	450.0	-	450.0
Repayment of long-term loans	(4.2)	(808.0)	(56.4)	(853.2)
Treasury shares	-	(35.0)	-	(35.0)
Repayment of shareholder loan	-	(93.6)	-	(93.6)
Dividend for 2009/2010	-	-	(11.6)	-
Non controlling interests, dividend etc.	(0.7)	(0.3)	(0.7)	(0.7)
<b>Cash flow from financing activities</b>	<b>(4.9)</b>	<b>(39.9)</b>	<b>(68.7)</b>	<b>(85.5)</b>
<b>Cash flow from discontinued operations</b>	<b>1.1</b>	<b>2.1</b>	<b>4.0</b>	<b>2.8</b>
<b>Net cash flow for the period</b>	<b>84.9</b>	<b>(6.6)</b>	<b>59.9</b>	<b>(22.6)</b>
Cash and cash equivalents at beginning of period	33.6	67.1	61.0	80.3
Unrealised exchange gain included in cash and cash equivalents	(0.4)	0.5	(2.8)	3.3
Net cash flow for the period	84.9	(6.6)	59.9	(22.6)
<b>Cash and cash equivalents at August 31</b>	<b>118.1</b>	<b>61.0</b>	<b>118.1</b>	<b>61.0</b>

## SEGMENT INFORMATION

EUR million	Q4 2010/11				
Income statement	Cultures & Enzymes	Health & Nutrition	Natural Colors	Not allocated	Group
External revenue	97.5	23.9	40.1		161.5
EUR growth	1%	18%	8%		5%
Organic growth	5%	24%	12%		9%
EBITDA (b.s.i.)	41.7	11.0	4.4		57.1
EBITDA margin (b.s.i.) (%)	43%	46%	11%		35%
Special items					-
EBITDA	41.7	11.0	4.4		57.1
EBITDA margin (%)	43%	46%	11%		35%
Depreciation, amortization and impairment losses	(8.2)	(1.7)	(1.3)		(11.2)
EBIT	33.5	9.3	3.1		45.9
EBIT margin (%)	34%	39%	8%		28%

	2010/11				
Income statement	Cultures & Enzymes	Health & Nutrition	Natural Colors	Not allocated	Group
External revenue	378.8	90.9	165.9		635.6
EUR growth	6%	15%	42%		15%
Organic growth	6%	16%	40%		14%
EBITDA (b.s.i.)	143.3	36.8	21.6		201.7
EBITDA margin (b.s.i.) (%)	38%	40%	13%		32%
Special items					-
EBITDA	143.3	36.8	21.6		201.7
EBITDA margin (%)	38%	40%	13%		32%
Depreciation, amortization and impairment losses	(32.0)	(6.4)	(4.1)		(42.5)
EBIT	111.3	30.4	17.5		159.2
EBIT margin (%)	29%	33%	11%		25%

## SEGMENT INFORMATION

EUR million

Q4 2009/10

Income statement	Cultures & Enzymes	Health & Nutrition	Natural Colors	Not allocated	Group
External revenue	96.6	20.3	37.2		154.1
EUR growth	7%	13%	79%		6%
Organic growth	2%	2%	66%		12%
EBITDA (b.s.i.)	41.6	8.6	5.1		55.3
EBITDA margin (b.s.i.) (%)	43%	42%	14%		36%
Special items				(1.6)	(1.6)
EBITDA	41.6	8.6	5.1	(1.6)	53.7
EBITDA margin (%)	43%	42%	14%		35%
Depreciation, amortization and impairment losses	(8.5)	(1.4)	(1.3)		(11.2)
EBIT	33.1	7.2	3.8	(1.6)	42.5
EBIT margin (%)	34%	35%	10%		28%

2009/10

Income statement	Cultures & Enzymes	Health & Nutrition	Natural Colors	Not allocated	Group
External revenue	356.2	78.8	116.8		551.8
EUR growth	8%	15%	48%		15%
Organic growth	6%	14%	42%		13%
EBITDA (b.s.i.)	137.7	27.8	16.4		181.9
EBITDA margin (b.s.i.) (%)	39%	35%	14%		33%
Special items				(24.2)	(24.2)
EBITDA	137.7	27.8	16.4	(24.2)	157.7
EBITDA margin (%)	39%	35%	14%		29%
Depreciation, amortization and impairment losses	(33.4)	(4.6)	(4.1)		(42.1)
EBIT	104.3	23.2	12.3	(24.2)	115.6
EBIT margin (%)	29%	29%	11%		21%

## SEGMENT INFORMATION

EUR million		Aug 31, 2011			
Assets	Cultures & Enzymes	Health & Nutrition	Natural Colors	Not allocated	Group
Goodwill	535.1	76.2	-		611.3
Other intangible assets	131.5	46.4	14.7		192.6
Intangible assets	666.6	122.6	14.7		803.9
Tangible assets	186.6	30.1	27.4		244.1
<b>Total non-current assets excluding deferred tax</b>	<b>853.2</b>	<b>152.7</b>	<b>42.1</b>		<b>1,048.0</b>
Inventories	39.0	9.4	29.7		78.1
Trade receivables	48.5	12.6	24.5		85.6
Trade payables	(30.4)	(7.2)	(28.6)		(66.2)
<b>Net working capital</b>	<b>57.1</b>	<b>14.8</b>	<b>25.6</b>		<b>97.5</b>
<b>Invested capital</b>	<b>375.2</b>	<b>91.3</b>	<b>67.7</b>		<b>534.2</b>
<b>ROIC, excluding goodwill, % adjusted for divestment</b>	<b>30%</b>	<b>34%</b>	<b>27%</b>		<b>30%</b>

		Aug 31, 2010			
Assets	Cultures & Enzymes	Health & Nutrition	Natural Colors	Not allocated	Group
Goodwill	547.8	77.8	-		625.6
Other intangible assets	134.2	40.9	15.1		190.2
Intangible assets	682.0	118.7	15.1		815.8
Tangible assets	187.5	34.5	36.5		258.5
<b>Total non-current assets excluding deferred tax</b>	<b>869.5</b>	<b>153.2</b>	<b>51.6</b>		<b>1,074.3</b>
Inventories	34.5	10.4	30.4		75.3
Trade receivables	51.2	11.5	20.2		82.9
Trade payables	(32.4)	(7.5)	(24.7)		(64.6)
<b>Net working capital</b>	<b>53.3</b>	<b>14.4</b>	<b>25.9</b>		<b>93.6</b>
<b>Invested capital</b>	<b>375.0</b>	<b>89.8</b>	<b>77.5</b>		<b>542.3</b>
<b>ROIC, excluding goodwill, % adjusted for divestment</b>	<b>28%</b>	<b>27%</b>	<b>21%</b>		<b>27%</b>

## SEGMENT INFORMATION

EUR million

Geographical allocation

Revenue	Q4	Q4	2010/11	2009/10
	2010/11	2009/10	2010/11	2009/10
Denmark	2.3	2.5	9.1	8.7
Rest of Europe	79.9	78.1	314.2	274.9
Asia, Pacific, Midle East & Africa	24.3	21.4	103.3	84.2
North America	35.1	34.4	133.6	122.0
South America	19.9	17.7	75.4	62.0
<b>Revenue, total</b>	<b>161.5</b>	<b>154.1</b>	<b>635.6</b>	<b>551.8</b>

Non-current assets, excl. deferred tax

Denmark	619.5	609.3
Rest of Europe	260.4	278.6
Asia, Pacific, Midle East & Africa	16.2	14.8
North America	114.9	132.2
South America	37.0	39.4
<b>Non-current assets, total</b>	<b>1,048.0</b>	<b>1,074.3</b>